ACC.19: 3 Studies in Cardioprotection

News
Slideshow

Dapagliflozin, icosapent ethyl, and bempedoic acid were found to reduce clinical or surrogate CV endpoints in studies presented at ACC.19, March 16-18, in New Orleans, LA.

Recent Videos
New Research Amplifies Impact of Social Determinants of Health on Cardiometabolic Measures Over Time
Where Should SGLT-2 Inhibitor Therapy Begin? Thoughts from Drs Mikhail Kosiborod and Neil Skolnik
Related Content
Weight Cycling Ups Risk for Heart Failure by 50%, Other Metabolic Diseases by Up to 30%: New Data

Weight Cycling Ups Risk for Heart Failure by 50%, Other Metabolic Diseases by Up to 30%: New Data

Grace Halsey
June 23rd 2025
Article

Weight cycling significantly raises heart failure and metabolic disease risks, independent of baseline overweight, underscoring the importance of stable weight strategies.

Navigating Cardiovascular Complications of Obesity: Expert Insights for Primary Care

Navigating Cardiovascular Complications of Obesity: Expert Insights for Primary Care

Sydney Jennings
August 30th 2023
Podcast

Listen to our latest podcast episode for details on top CVD risk factors to screen patients with obesity for, medications to help prevent CVD, and more.

Healthy Low-Carb or Low-Fat Diets Linked to Lower CVD Risk: Daily Dose / image credit: ©New Africa/AdobeStock

Healthy Low-Carb or Low-Fat Diets Linked to Lower CVD Risk: Daily Dose

Sydney Jennings
June 19th 2025
Article

Your daily dose of the clinical news you may have missed.

Primary Viewpoints Episode 4: Lp(a): The Next CVD Target?

Primary Viewpoints Episode 4: Lp(a): The Next CVD Target?

Patient Care Editorial Staff
October 29th 2020
Podcast

Patrick Moriarty, MD, from the University of Kansas Medical Center, discusses the role of Lp(a) as a risk factor for cardiovascular disease and the phase 3 trials of a potential treatment.

/ image credit Cathy Goldstein, MD Courtesy of Michigan Neuroscience Institute

Validation Study of SANSA Home Sleep Apnea Test Published in Frontiers in Neurology, Huxley Medical Announces

Grace Halsey
June 18th 2025
Article

Huxley Medical's SANSA home sleep apnea test matched traditional PSG in accuracy and significantly simplifies OSA assessment and diagnosis for patients and HCPs.

Universal Low-Dose Aspirin Prescribing Strategy May be Beneficial for Preeclampsia Prevention

Universal Low-Dose Aspirin Prescribing Strategy May be Beneficial for Preeclampsia Prevention

Sydney Jennings
June 18th 2025
Article

Research presented at ACOG 2025 showed 99% of pregnant women included in the analysis were eligible for aspirin, per ACOG guidelines.

© 2025 MJH Life Sciences

All rights reserved.